Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynthomer Regulatory News (SYNT)

Share Price Information for Synthomer (SYNT)

Share Price is delayed by 15 minutes
Get Live Data
105.20    2.00 (1.94%)
Bid:
104.40
Ask:
105.20
Spread: 0.80 (0.766%)
Market Cap: £172.47m
SYNT Live PriceLast checked at - London Stock Exchange

Intraday Synthomer Share Chart

Disposal

5 Jan 2009 11:17

RNS Number : 0853L
Yule Catto & Co PLC
05 January 2009
 

5 January 2009

Yule Catto & Co plc

Disposal of Oxford Chemicals Limited

Yule Catto & Co plc ("the Group"), an international producer of specialty chemicals used in a wide range of industries including pharmaceuticals, FMCG, paints and adhesivesis pleased to announce that it has exchanged conditional contracts with Frutarom (UK) Limited for the sale of the business and assets of Oxford Chemicals Limited for a consideration of £8.25 million.  The consideration will be paid in full in cash at completion.

The completion of the sale is conditional on regulatory approval for the transfer of operational licences and compliance with employee information and consultation requirements.

The proceeds of the sale will be used to reduce the Group's borrowings.

Oxford Chemicals develops, manufactures and supplies high impact aroma chemicals and other specialty aroma chemicals In the twelve months to 31 December 2007 it had sales of £9.7 million, an operating profit of £0.6 million and gross assets of £6.4 million.

The Oxford Chemicals management team led by Anthony Weston will continue to run the business.

Adrian Whitfield, Chief Executive, commented:

"We are now in the final stages of implementing our stated strategy of divesting the Impact Chemicals division, with gross proceeds to date reaching some £63 million."

Recent update

Yule Catto issued an update on 29 December 2008, the full text of which is repeated below.

Yule Catto & Co plc ("the Group") is pleased to announce that it has signed a new three year £30 million revolving loan facility with its principal banks, HSBC and Barclays. This loan replaces its existing revolving bank loan facility maturing in November 2009.

During the course of this re-financing, the Board has been carefully considering the capital structure of the Group. Whilst much progress has been made on the deleveraging of the balance sheet, with £55 million of gross proceeds received from the sale of three of our five Impact Chemicals businesses*, the balance sheet remains a core focus of the Board and it aims to reduce outstanding net debt to below £100 million over the next twelve to twenty four months. The Board believes this is consistent with the Group's objectives, including its financial commitments to the Group's UK pension fund.

Accordingly, and in light of the current financial environment and economic uncertainty, the Board has additionally decided to suspend the payment of dividends until such time as net debt is nearer to its overall target and at which time the business environment and financial market conditions may well have improved. The Board anticipates reverting to the payment of a dividend within two years.

At the time the Group recommences the payment of a dividend, the Board anticipates rebasing it to a level determined by comparison with its peer group and which will allow an appropriate free cash flow to suit the Group's circumstances.

The Board is also pleased to confirm that for 2008 the Group still expects to deliver underlying earnings before tax modestly ahead of last year, despite the current difficult economic conditions particularly in the UK and Continental Europe. The Board believes it is too early at this time, given the prevailing economic uncertainty, to offer any firm guidance on the outturn for 2009. The Group's Impact Chemicals and Pharma Chemicals businesses should benefit next year from recent restructuring. Within our Polymer Chemicals business we anticipate the performance of our Asian and Middle East businesses to be more robust than that of our European businesses, due to local market conditions and a more resilient demand profile from our targeted markets. In addition, the current relative weakness of Sterling against the Dollar, Euro and Malaysian Ringgit, should it continue, will assist the reported Sterling earnings for a number of our businesses.

The Group continues to look at ways to improve efficiency and minimise costs. We currently have a number of initiatives in hand to do this, both within Europe and the rest of the world. 

These are exceptional times, with a high degree of market uncertainty and a very difficult environment for funding. Having completed £55 million of divestments* and put in place a new revolving loan, the Board believes that, together with internal actions to conserve cash and the suspension of the dividend, Yule Catto is now well placed to weather these conditions.

(* before the disposal of Oxford Chemicals announced today)

- Ends -

For further information, please contact:

 

Yule Catto & Co plc 
Adrian Whitfield, Chief Executive 
David Blackwood, Group Finance Director
 
01279 442791
Hogarth Partnership
John Olsen
Andrew Jaques
Ian Payne
020 7357 9477
07770 272082

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DISILFLLLSIEIIA
Date   Source Headline
29th Sep 20227:00 amRNSTrading update
23rd Sep 20229:23 amRNSHolding(s) in Company
12th Sep 20223:27 pmRNSHolding(s) in Company
6th Sep 20228:15 amRNSHolding(s) in Company
12th Aug 20229:22 amRNSDirector/PDMR Shareholding
11th Aug 20227:00 amRNSDirector/PDMR Shareholding
9th Aug 20224:09 pmRNSHolding(s) in Company
9th Aug 20227:00 amRNSDirector/PDMR Shareholding
5th Aug 20221:20 pmRNSHolding(s) in Company
5th Aug 202211:27 amRNSDirector/PDMR Shareholding
4th Aug 20222:57 pmRNSDirector/PDMR Shareholding
4th Aug 20222:35 pmRNSDirector/PDMR Shareholding
3rd Aug 202212:29 pmRNSDirector/PDMR Shareholding
2nd Aug 20227:00 amRNSResults for the six months ended 30 June 2022
15th Jul 20222:32 pmRNSHolding(s) in Company
8th Jul 202210:23 amRNSHolding(s) in Company
1st Jul 20227:00 amRNSChief Financial Officer
30th Jun 20225:04 pmRNSHolding(s) in Company
21st Jun 20227:00 amRNSAppointment of Non-Executive Director
17th May 202212:55 pmRNSHolding(s) in Company
5th May 202212:39 pmRNSHolding(s) in Company
4th May 20224:46 pmRNSDirector/PDMR Shareholding
4th May 20227:00 amRNSAppointment of Joint Corporate Brokers
28th Apr 202212:24 pmRNSResult of AGM
28th Apr 20227:00 amRNSQ1 2022 trading update
26th Apr 20229:33 amRNSHolding(s) in Company
20th Apr 20224:13 pmRNSHolding(s) in Company
5th Apr 20224:18 pmRNSDirector/PDMR Shareholding
1st Apr 20221:34 pmRNSCompletion of adhesives acquisition
29th Mar 20223:17 pmRNSHolding(s) in Company
29th Mar 20223:14 pmRNSDirector/PDMR Shareholding
25th Mar 20222:03 pmRNSAnnual Financial Report
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:50 pmRNSDirector/PDMR Shareholding
14th Mar 202212:48 pmRNSDirector/PDMR Shareholding
14th Mar 20229:35 amRNSHolding(s) in Company
9th Mar 202212:52 pmRNSDirector/PDMR Shareholding
8th Mar 20223:22 pmRNSDirector/PDMR Shareholding
8th Mar 20223:19 pmRNSDirector/PDMR Shareholding
3rd Mar 20227:00 amRNSPreliminary Results for the year ended 31 Dec 2021
14th Feb 20227:00 amRNSPre-close trading update
10th Feb 20223:10 pmRNSNOTIFICATION OF MAJOR HOLDINGS
22nd Dec 20215:10 pmRNSDirector/PDMR Shareholding
21st Dec 20213:09 pmRNSDirector/PDMR Shareholding
20th Dec 20213:40 pmRNSDirector/PDMR Shareholding
17th Dec 202112:29 pmRNSResults of General Meeting
15th Dec 20212:54 pmRNSDirector/PDMR Shareholding
30th Nov 20214:57 pmRNSPUBLICATION OF CIRCULAR
26th Nov 20217:00 amRNSAppointment of Chief Financial Officer
22nd Nov 202110:36 amRNSDirector Declaration

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.